{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:26:04Z","timestamp":1791591964999,"version":"4.3.4"},"reference-count":15,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":187,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:p>Meclizine, an antihistamine, has been widely used for prophylactic treatment and management of motion sickness. However, the onset of action of meclizine was about 1 hour for the treatment of motion sickness and vertigo. A new suspension formulation of meclizine (MOS) was developed with the intention to achieve a rapid effect. To investigate the pharmacokinetics of the new MOS formulation versus the marketed meclizine oral tablet (MOT), a phase 1 pharmacokinetic study was performed in 20 healthy volunteers. In addition, an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme was also performed to determine the metabolic pathway in the human body. The plasma concentration of MOS appeared more rapidly in comparison to the MOT. The geometric mean ratios (90% confidence interval) of AUC<jats:sub>0\u201324<\/jats:sub>and AUC<jats:sub>0\u2010\u221e<\/jats:sub>indicated no significant difference in bioavailability between the 2 formulations. CYP2D6 was found to be the dominant enzyme for metabolism of meclizine, and its genetic polymorphism could contribute to the large interindividual variability. In view of the similar bioavailability with a much shorter peak time of the plasma meclizine concentration from the MOS formulation, this new formulation is expected to produce a much quicker onset of action when used for the management of motion sickness.<\/jats:p>","DOI":"10.1177\/0091270011414575","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T15:24:35Z","timestamp":1315581875000},"page":"1343-1349","source":"Crossref","is-referenced-by-count":37,"title":["Meclizine Metabolism and Pharmacokinetics: Formulation on Its Absorption"],"prefix":"10.1002","volume":"52","author":[{"given":"Zhijun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses S. S.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_7_2_2","volume-title":"Antivert oral tablets, meclizine hydrochloride [product information]","year":"1999"},{"issue":"6","key":"e_1_2_7_3_2","first-page":"560","article-title":"Motion\u2010sickness medications for aircrew: impact on psychomotor performance","volume":"76","author":"Paul MA","year":"2005","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_7_4_2","volume-title":"American Hospital Formulary Service Drug Information","author":"American Hospital Formulary Service, Board of American Society of Health\u2010System Pharmacists.","year":"2009"},{"key":"e_1_2_7_5_2","first-page":"1","article-title":"2008 top 200 generic drugs by retail dollars","year":"2009","journal-title":"Drug Topics"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/bms.1200050806"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600741022"},{"issue":"2","key":"e_1_2_7_8_2","first-page":"105","article-title":"Biotransformation of meclizine in the human body","volume":"26","author":"Goenechea VS","year":"1988","journal-title":"J Clin Chem Clin Biochem"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0022-3565(25)26997-X","article-title":"Metabolism of meclizine in the rat","volume":"147","author":"Narrod SA","year":"1965","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_10_2","volume-title":"AMA Drug Evaluations","author":"AMA Department of Drugs.","year":"1986"},{"key":"e_1_2_7_11_2","volume-title":"The Extra Pharmacopeia","author":"Martindale RJ","year":"1997"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2010.11.022"},{"key":"e_1_2_7_13_2","unstructured":"Meclizine Drugdex Micromedex\u00ae Healthcare series 2009.www.thomsonhc.com."},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/11318030-000000000-00000"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/10937400903158342"},{"issue":"2","key":"e_1_2_7_16_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","article-title":"CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure","volume":"17","author":"Sistonen JA","year":"2007","journal-title":"Pharmacogenet Genom"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270011414575","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270011414575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T08:25:13Z","timestamp":1741595113000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270011414575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1177\/0091270011414575"],"URL":"https:\/\/doi.org\/10.1177\/0091270011414575","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}